Future therapies for eosinophilic gastrointestinal disorders

Ann Allergy Asthma Immunol. 2020 Mar;124(3):219-226. doi: 10.1016/j.anai.2019.11.018. Epub 2019 Nov 26.

Abstract

Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs).

Data sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed.

Study selections: Studies on treatment and clinical trials in EGIDs were included in this review.

Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development.

Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biological Therapy
  • Biomarkers
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Disease Management
  • Disease Susceptibility
  • Enteritis / diagnosis
  • Enteritis / etiology
  • Enteritis / metabolism
  • Enteritis / therapy*
  • Eosinophilia / diagnosis
  • Eosinophilia / etiology
  • Eosinophilia / metabolism
  • Eosinophilia / therapy*
  • Gastritis / diagnosis
  • Gastritis / etiology
  • Gastritis / metabolism
  • Gastritis / therapy*
  • Humans
  • Molecular Targeted Therapy
  • Standard of Care
  • Treatment Outcome

Substances

  • Biomarkers

Supplementary concepts

  • Eosinophilic enteropathy